Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03192176 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 356
- Enrollment target
NCT03192176 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 356 participants.
The verdict
NCT03192176, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 356 participants
- Enrollment target
Study Summary
This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.
Interventions
- DRUG Placebo
- DRUG Fezolinetant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2018-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03192176
The ClinicalTrials.gov registry entry for NCT03192176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03192176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03192176 about?
NCT03192176 is a clinical study titled "A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)". This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.
What is the current status of trial NCT03192176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 356 participants. The study started on 2017-07-19. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT03192176?
The interventions under investigation include: Placebo (DRUG), Fezolinetant (DRUG).
Who is sponsoring clinical trial NCT03192176?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.